Prelude Therapeutics' Series B Round

Prelude Therapeutics raised a round of funding on October 20, 2017. Investors include OrbiMed Advisors.

Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases.…

Articles about Prelude Therapeutics' Series B Round: